Inspire Pharmaceuticals discovered and developed breakthrough products to treat diseases involving impaired hydration of the body's mucosal surfaces such as chronic bronchitis and dry eye disease. The products were targeted at disorders with high unmet medical needs representing large, near-term market opportunities. Inspire had an initial public offering in 2000 and was acquired by Merck in 2011.